One-Shot gene therapy tested to halt devastating autoimmune attacks
NCT ID NCT07413341
Summary
This early-stage study is testing a new, one-time treatment called TI-0032-III for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard drugs. The treatment uses an injection to genetically reprogram the patient's own immune cells to target and reduce harmful B cells. The main goals are to see if this approach is safe and if it can help control these difficult-to-treat conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Changzheng Hospital
RECRUITINGShanghai, Shanghai Municipality, 200003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.